Abilify Digital Approval Status
- FDA approved: No
- Brand name: Abilify Digital
- Generic name: aripiprazole
- Company: Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health
- Treatment for: Schizophrenia, Bipolar Disorder
Abilify Digital (aripiprazole) is a tablet formulation of an approved atypical antipsychotic embedded with an ingestible Proteus® sensor that communicates with a wearable sensor patch and a medical software application in development for measuring adherence in the treatment of adults with schizophrenia, bipolar I disorder, and major depressive disorder.
On April 26, 2016, Otsuka and Proteus announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for their Digital Medicine, a drug/device combination product. The FDA completed its review and has requested additional information, including data regarding the performance of the product under the conditions in which it is likely to be used, and further human factors investigations.
Development Status and FDA Approval Process for Abilify Digital
|Apr 26, 2016||FDA Issues Complete Response Letter for Digital Medicine New Drug Application|
|Sep 10, 2015||U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.